paradigm shift

REPURPOSING


Established drugs can be repurposed for new clinical indications for unmet medical needs when protected by strong intellectual property. Historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs.

READ MORE

UNDERSTANDING COMPLEXITY


Life is complex! For every diagnosis, there are multiple factors and biological interactions involved. We develop therapeutics targeting multiple pathways involved in injury or on the road to disease producing better outcomes for patients.

READ MORE

our focus

PENTOSAN POLYSULPHATE SODIUM (PPS)


We focus on PPS because this FDA approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and respiratory disease.

READ MORE

INFLAMMATION


Inflammation is a complex biological response to injury, infection or allergy, which has short and long term components mediated by factors produced by immune cells.

READ MORE

announcements

Ross River Virus breakthrough

8 September 2016
Paradigm’s drug PPS treats painful joint inflammation symptoms caused by mosquito-borne Ross River Virus infections.

READ MORE

Zilosul® clinical trial starts

26 February 2016
Paradigm commences clinical trial to investigate Zilosul® as a treatment for bone bruising following ACL injury.

READ MORE

European Patent Secured

15 December, 2015
Paradigm Biopharmaceuticals secures key European patent.

READ MORE

key statistics

Allergic rhinitis (AR)

2016 National Study of Allergic Rhinitis costs to workers in Sweden showed AR cost 3-4x greater than asthma; substantially higher than expected at $US1.4 billion (population 9.5 million); 70% of cost due to reduced working capacity.


Allergic rhinitis (AR)

2008 data indicates that 600 million people worldwide suffer from AR.

In US 2010 nasal swelling cost $US17.5 billion, 6 million work/school days lost, 16 million visits to doctor.


Bone Marrow Edema (BME)

Worldwide hip & knee surgical implant market is $16.7 billion, will be $33 billion by 2022. Acute joint injury leads to osteoarthritis.


Bone Marrow Edema (BME)

>50% top ranked skiers have injured knee ligaments (women 5x more susceptible than men)

clinical

CLINICAL TRIALS

We have programs in Ross River fever and Osteoarthritis entering clinical trials in 2017

READ MORE

PIPELINE


READ MORE

RESEARCH & DEVELOPMENT

Paradigm is evaluating new intellectual property that has relevance to treating inflammation, especially in orthopaedics.


READ MORE

our partners

  • partner_logos_1
  • partner_logos_2b